Free Newsletter
Cash-poor patients cut back on meds
Pharma stock may be something of a safe haven for investors battered by the yo-yo markets, but as the turmoil continues to leak from Wall Street to Main Street, drugmakers themselves may suffer. In fact, cash-strapped Americans are already cutting back on healthcare. That's big news, because healthcare has historically been seen as a port for every recessionary storm.
Scrips fell by 0.5 percent during the first quarter, year-over-year, and almost 2 percent during the second. The first negative quarters in more than a decade, according to IMS Health. Plus, 11 percent of consumers surveyed by the National Association of Insurance Commissioners said they've cut back on prescription drugs to save money. They're also cutting back on elective surgeries such as hip and knee replacements--and along with them, all the anesthesia meds, painkillers, antibiotics, and other meds they'd be given in the hospital.
People are skipping pills, postponing refills, and switching to cheaper alternatives to their current meds. Will the trend continue long enough to make a big dent in Big Pharma's bottom line? Your reading of the economic tea leaves is probably as good or better than ours.
- read the Wall Street Journal story
Related Articles:
Congress decries drug price-gouging
Americans prioritize medication prices
GSK tops rankings on drug access for poor
Economic crisis rips biotech's bargaining position
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FiercePharma email newsletter for FREE!
Be the first to comment